Inflammatory Response after Implantation of a Left Ventricular Assist Device: Comparison between the Axial Flow MicroMed DeBakey VAD and the Pulsatile Novacor Device

The implantation of a ventricular assist device (VAD) is associated with a stimulation of the inflammatory system. We compared changes in the inflammatory response after implantation of a pulsatile Novacor left (L) VAD and the axial flow MicroMed DeBakey VAD. Six consecutive patients after implantation of a Novacor LVAD (NC) and six patients after implantation of a MicroMed DeBakey VAD (MD) were included in the investigation. Patients received LVADs for medically non treatable end-stage heart failure. Tumor necrosis factor alpha (TNF), C3a, C5a, interleukin 6 (IL-6), and neutrophil elastase were measured twice a week over a period of 3 months after implantation of the device. All tests were performed with an enzyme-linked immunosorbent assay. There was no significant difference in the clinical course of the two groups. All inflammatory parameters were elevated in both groups during the entire period of the investigation. There was no difference in TNF, polynuclear leukocyte elastase, or C3a levels between the two groups; however, IL-6 (NC: 23.6 ± 37.6 pg/ml vs. MD: 63 ± 114 pg/ml, p < 0.001) and C5a (NC: 708 ± 352 &mgr;g/L vs. MD: 1,745 ± 1,305 &mgr;g/L, p < 0.001) were increased significantly more in patients following implantation of the axial flow MicroMed DeBakey VAD. Compared with the pulsatile Novacor device, the implantation of the axial flow MicroMed DeBakey LVAD seems to be associated with an increased stimulation of one part of the inflammatory system. Further investigations are necessary for evaluation of the pathophysiologic mechanism and clinical implications of these findings.

[1]  R. Hetzer,et al.  Alterations in coagulation after implantation of a pulsatile Novacor LVAD and the axial flow MicroMed DeBakey LVAD. , 2000, The Annals of thoracic surgery.

[2]  M E DeBakey,et al.  A miniature implantable axial flow ventricular assist device. , 1999, The Annals of thoracic surgery.

[3]  H. Scheld,et al.  Left Ventricular Assist System Support Is Associated With Persistent Inflammation and Temporary Immunosuppression , 1999, The Thoracic and cardiovascular surgeon.

[4]  W. Richenbacher,et al.  Time course of cytokine release and complement activation after implantation of the HeartMate left ventricular assist device. , 1998, ASAIO journal.

[5]  R. Hetzer,et al.  Complement activation in patients undergoing mechanical circulatory support. , 1998, ASAIO journal.

[6]  P. Ward,et al.  Complement, cytokines, and adhesion molecule expression in inflammatory reactions. , 1998, Proceedings of the Association of American Physicians.

[7]  W. Wagner,et al.  Monocyte tissue factor expression and ongoing complement generation in ventricular assist device patients. , 1998, The Annals of thoracic surgery.

[8]  C. Hack,et al.  Interleukin-6 Downregulates Factor XII Production by Human Hepatoma Cell Line (HepG2) , 1997 .

[9]  M. Gascon,et al.  The Coagulation and Fibrinolytic Responses of Baboons after In Vivo Thrombin Generation – Effect of Interleukin 6 , 1997, Thrombosis and Haemostasis.

[10]  T. Horiuchi,et al.  C5a Induces Tissue Factor Activity on Endothelial Cells , 1997, Thrombosis and Haemostasis.

[11]  R. Hetzer,et al.  Blood Contact with Artificial Surfaces during BVAD Support , 1996, The International journal of artificial organs.

[12]  E. Moore,et al.  Interleukin‐6 stimulates neutrophil production of platelet‐activating factor , 1996, Journal of leukocyte biology.

[13]  R. Colman,et al.  Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. , 1996, Blood.

[14]  J. Dutcher,et al.  Alterations in platelet function in patients receiving interleukin-6 as cytokine therapy. , 1996, Cancer investigation.

[15]  R. Hetzer,et al.  Interleukin‐6 and interleukin‐8 concentrations as predictors of outcome in ventricular assist device patients before heart transplantation , 1994, Critical care medicine.

[16]  T. Andus,et al.  Human recombinant C5a enhances lipopolysaccharide‐induced synthesis of interleukin‐6 by human monocytes , 1992, European journal of clinical investigation.

[17]  J. Shinn Novacor left ventricular assist system. , 1991, AACN clinical issues in critical care nursing.